
Opinion|Videos|February 24, 2025
Sequential Therapy in Myelofibrosis: Evidence-Based Strategies for Treatment Transitions
Author(s)Aaron T. Gerds, MD, MS, Jeanne Palmer, MD
Panelists discuss how treatment sequencing decisions in myelofibrosis should be guided by clinical evidence, patient response patterns, and strategic consideration of future therapeutic options to maintain long-term disease control.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dual BCMA/CD19 CAR T, AZD0120, Yields 96% ORR in Myeloma; Fast Turnaround
2
NCCN Guidelines in nccRCC Weigh New Data for Combinations
3
CARTITUDE-4: Cilta-Cel May Offer Curative Potential in Standard-Risk R/R Myeloma
4
Microbiota-Based MaaT013 Shows Strong Efficacy in Refractory GI-aGVHD
5









































